Back

The Novel Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes

chen, y.; Feng, Z.; Diao, B.; Wang, R.; Wang, G.; Wang, C.; Tan, Y.; Liu, L.; Wang, C.; Liu, Y.; Liu, Y.; Yuan, Z.; Ren, L.; Wu, Y.

2020-03-31 infectious diseases
10.1101/2020.03.27.20045427 medRxiv
Show abstract

While lymphocytopenia is a common characteristic of patients infected by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the mechanisms responsible for this depletion are unclear. Through careful inspection of the spleens and lymph nodes (LNs) from six cases with postmortem examinations, we observed that SARS-CoV-2 could directly infect secondary lymphoid organs to induce cell death. Immunohistochemistry demonstrated ACE2 (angiotensin-converting enzyme 2), the potential receptor of SARS-CoV-2, expresses on tissue-resident CD169+ macrophages in spleens and LNs. Immunofluorescent staining confirmed that viral nucleocaspid protein (NP) can be found in ACE2+ cells, CD169+ macrophages, but not in CD3+ T cells or B220+ B cells in spleens and LNs. SARS-CoV-2 infection induces severe tissue damage including lymph follicle depletion, splenic nodule atrophy, histiocyte hyperplasia and lymphocyte reductions. Moreover, in situ TUNEL staining illustrated that viral infection leads to severe lymphocyte apoptosis, which might be mediated by viral antigens inducing Fas upregulation. Furthermore, SARS-CoV-2 also triggers macrophages to produce IL-6, a proinflammatory cytokine that directly promotes lymphocyte necrosis. Collectively, these results demonstrate that SARS-CoV-2 directly neutralizes human spleens and LNs through infecting tissue-resident CD169+ macrophages.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
Signal Transduction and Targeted Therapy
30 papers in training set
Top 0.1%
6.7%
2
Frontiers in Immunology
638 papers in training set
Top 2%
6.2%
3
Journal of Virology
499 papers in training set
Top 1%
5.5%
4
Journal of Medical Virology
140 papers in training set
Top 0.3%
5.4%
5
Scientific Reports
3612 papers in training set
Top 23%
4.3%
6
JCI Insight
277 papers in training set
Top 1%
4.3%
7
The Journal of Infectious Diseases
202 papers in training set
Top 0.8%
4.3%
8
Virologica Sinica
11 papers in training set
Top 0.1%
4.0%
9
Microbiology Spectrum
469 papers in training set
Top 4%
3.5%
10
PLOS Pathogens
820 papers in training set
Top 4%
3.5%
11
eLife
5828 papers in training set
Top 38%
2.7%
50% of probability mass above
12
PLOS ONE
5266 papers in training set
Top 41%
2.6%
13
International Journal of Infectious Diseases
129 papers in training set
Top 0.9%
2.4%
14
Journal of Biomedical Science
17 papers in training set
Top 0.1%
2.4%
15
Journal of Molecular Cell Biology
22 papers in training set
Top 0.1%
2.1%
16
Cellular & Molecular Immunology
14 papers in training set
Top 0.1%
2.1%
17
Viruses
332 papers in training set
Top 2%
2.1%
18
Journal of Cellular Physiology
25 papers in training set
Top 0.2%
1.9%
19
mBio
833 papers in training set
Top 8%
1.7%
20
Pathogens
56 papers in training set
Top 0.6%
1.7%
21
iScience
1154 papers in training set
Top 23%
1.3%
22
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 35%
1.1%
23
Emerging Microbes & Infections
74 papers in training set
Top 0.9%
1.1%
24
Nature Communications
5641 papers in training set
Top 51%
1.1%
25
Virology Journal
32 papers in training set
Top 0.7%
1.0%
26
Clinical Infectious Diseases
235 papers in training set
Top 2%
1.0%
27
The Innovation
13 papers in training set
Top 0.2%
1.0%
28
Journal of Clinical Investigation
179 papers in training set
Top 5%
1.0%
29
Journal of Advanced Research
14 papers in training set
Top 0.2%
0.9%
30
Frontiers in Microbiology
427 papers in training set
Top 8%
0.8%